Hormonal Modulation in the Treatment of Breast Cancer

Endocrinology and Metabolism Clinics of North America

Volumn 40, Issue 3, 2011, Pages 519-532

  Adelson, Kerin ^a   Germain, Doris ^a   Raptis, George ^a   Biran, Noa ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Antiestrogens; Aromatase inhibitors; Breast cancer; GnRH agonist; Hormonal modulation; Ovarian suppression; SERD; SERM

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CONJUGATED ESTROGEN; CYCLIN D1; CYTOCHROME P450 2D6; DIETHYLSTILBESTROL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; FULVESTRANT; GOSERELIN; HORMONE; LETROZOLE; LEUPRORELIN; MEGESTROL ACETATE; PLACEBO; PROGESTERONE RECEPTOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE; TRASTUZUMAB;

ANXIETY; ARTHROPATHY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SCREENING; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DEPRESSION; DISEASE FREE SURVIVAL; DOWN REGULATION; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPAREUNIA; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FRAGILITY FRACTURE; GENOTYPE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; LIBIDO DISORDER; LOADING DRUG DOSE; LUNG EMBOLISM; METASTASIS POTENTIAL; OSTEOPOROSIS; OVARIECTOMY; OVARY FUNCTION; OVERALL SURVIVAL; PREDICTION; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; SLEEP DISORDER; STEADY STATE; SURVIVAL TIME; THROMBOEMBOLISM; THROMBOSIS; TUMOR ABLATION; UPREGULATION; VAGINA DISEASE; VAGINAL DRYNESS;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARCINOMA; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; RECEPTORS, ESTROGEN;

EID: 80052234771     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2011.05.011     Document Type: Review

References (61)

1. Altekruse S, Kosary C, Krapcho M, et al. SEER cancer statistics review, 1975-2007, National Cancer Institute. Bethesda, MD. Available at: Based on November 2009 SEER data submission, posted to the SEER web site, 2010. Accessed September 1, 2010. http://seer.cancer.gov/csr/1975_2007/.
2. Cancer facts and figures 2002, American Cancer Society, American Cancer Society, Atlanta (GA).
3. Fisher B. Biological and clinical considerations regarding the use of surgery and chemotherapy in the treatment of primary breast cancer. Cancer 1977, 40:574.
4. Jemal A., Ward E., Thun M.J. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 2007, 9:R28.
5. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321.
6. Love R.R., Philips J. Oophorectomy for breast cancer: history revisited. J Natl Cancer Inst 2002, 94:1433.
7. Schinzinger A. Ueber carcinoma mammae [abstract]. 18th Congress of the German Society for Surgery, Beilage zum Centralblatt fur Chirurgie 1889;16:55-6.
8. Beatson G. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment. Lancet 1896, 2:162.
9. Dellapasqua S., Colleoni M., Gelber R.D., et al. Adjuvant endocrine therapy for premenopausal women with early breast cancer. J Clin Oncol 2005, 23:1736.
10. Hughes L.L., Gray R.J., Solin L.J., et al. Efficacy of radiotherapy for ovarian ablation: results of a breast intergroup study. Cancer 2004, 101:969.
11. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687. (EBCTCG) EBCTG.
12. Sverrisdottir A, Johansson H, Johansson U, et al. Interaction between goserelin and tamoxifen in a controlled clinical trial of adjuvant endocrine therapy in premenopausal breast cancer. Presented at the 33rd Annual San Antonio Breast Cancer Symposium. San Antonio (TX), December 9, 2010.
13. Phase III randomized study of adjuvant therapy comprising tamoxifen citrate alone versus ovarian function suppression and tamoxifen citrate versus ovarian function suppression and exemestane in premenopausal women who have undergone surgery for hormone receptor-positive breast cancer (SOFT). Available at: Accessed June 23, 2011. http://clinicaltrials.gov/ct2/show/NCT00917969?term=premenopausal+breast+cancer&type=Intr&phase=2&rank=15.
14. Smith I.E., Ford H.T., Gazet J.C., et al. Premarin in the management of metastatic breast carcinoma in post-menopausal patients. Clin Oncol 1979, 5:159.
15. Ingle J.N., Ahmann D.L., Green S.J., et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 1981, 304:16.
16. Ellis M.J., Gao F., Dehdashti F., et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA 2009, 302:774.
17. Ansfield F.J., Davis H.L., Ellerby R.A., et al. A clinical trial of megestrol acetate in advanced breast cancer. Cancer 1974, 33:907.
18. Morgan L.R. Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients. Semin Oncol 1985, 12:43.
19. Muss H.B., Paschold E.H., Black W.R., et al. Megestrol acetate v tamoxifen in advanced breast cancer: a phase III trial of the Piedmont Oncology Association (POA). Semin Oncol 1985, 12:55.
20. Pritchard K. Should tamoxifen be used to treat premenopausal women with breast cancer?. Cancer Invest 2000, 18:685.
21. Harper M.J., Walpole A.L. Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature 1966, 212:87.
22. Klopper A., Hall M. New synthetic agent for the induction of ovulation: preliminary trials in women. Br Med J 1971, 1:152.
23. Jordan V.C. Antitumor activity of the antiestrogen ICI 46,474 (tamoxifen) in the dimethylbenzanthracene (DMBA)-induced rat mammary carcinoma model. J Steroid Biochem 1974, 5:354.
24. Cole M.P., Jones C.T., Todd I.D. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer 1971, 25:270.
25. Ovarian ablation in early breast cancer: overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1996, 348:1189. (EBCTCG) EBCTCG.
26. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998, 90:1371.
27. Fisher B., Dignam J., Wolmark N., et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1993, 353:1999.
28. Cuzick J, Sestak I, Pinder S, et al. Beneficial effect of tamoxifen for women with DCIS: long-term benefits from the UK/ANZ DCIS trial in women with locally excised DCIS. Presented at the 32nd Annual San Antonio Breast Cancer Symposium. San Antonio, December 10-13, 2009.
29. Tomas E., Kauppila A., Blanco G., et al. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol Oncol 1995, 59:261.
30. Milla-Santos A., Milla L., Rallo L., et al. Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer. Breast Cancer Res Treat 2001, 65:119.
31. Pagani O., Gelber S., Price K., et al. Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Ann Oncol 2004, 15:1749.
32. Cummings S.R., Eckert S., Krueger K.A., et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999, 281:2189.
33. Cauley J.A., Norton L., Lippman M.E., et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001, 65:125.
34. Vogel V.G., Costantino J.P., Wickerham D.L., et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res (Phila) 2010, 3:696.
35. Long X., Nephew K.P. Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-alpha. J Biol Chem 2006, 281:9607.
36. Howell A., Robertson J.F., Quaresma Albano J., et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002, 20:3396.
37. Osborne C.K., Pippen J., Jones S.E., et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002, 20:3386.
38. Howell A., Pippen J., Elledge R.M., et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer 2005, 104:236.
39. McCormack P., Sapunar F. Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer. Clin Breast Cancer 2008, 8:347.
40. Robertson J.F., Harrison M. Fulvestrant: pharmacokinetics and pharmacology. Br J Cancer 2004, 90(Suppl 1):S7.
41. Robertson J.F. Fulvestrant (Faslodex)-how to make a good drug better. Oncologist 2007, 12:774.
42. Di Leo A., Jerusalem G., Petruzelka L., et al. CONFIRM: a phase III randomized, parallel-group trial comparing fulvestrant 250 mg vs fulvestrant 500 mg in postemenopausal women with estrogen receptor-positive advanced breast cancer. Cancer Res 2009, 69:491S.
43. Robertson J, Lindemann J, Llombart-Cussac A, et al. A comparison of fulvestrant 500 mg with anastrozole as first-line treatment for advanced breast cancer: followup analysis from the FIRST study. Presented at the 33rd Annual San Antonio Breast Cancer Symposium. San Antonio, December 8-12, 2010.
44. Young O.E., Renshaw L., Macaskill E.J., et al. Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer. Eur J Cancer 2008, 44:391.
45. Goetz M.P., Rae J.M., Suman V.J., et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005, 23:9312.
46. Rae J, Drury S, Hayes D, et al. Lack of correlation between gene variants in tamoxifen metabolizing enzymes with primary endpoints in the ATAC trial. Presented at the 33rd Annual San Antonio Breast Conference. San Antonio (TX), December 9, 2010.
47. Leyland-Jones B., Regan M., Bouzyk M., et al. Outcome according to CYP2D6 Genotype among postmenopausal women with endocrine-responsive early invasive breast cancer randomized in the BIG 1-98 trial. Cancer Res 2010, 70:78S.
48. Buzdar A.U., Jonat W., Howell A., et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998, 83:1142.
49. Buzdar A.U., Jones S.E., Vogel C.L., et al. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Cancer 1997, 79:730.
50. Jonat W., Howell A., Blomqvist C., et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer Am 1996, 32:404.
51. Buzdar A., Douma J., Davidson N., et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001, 19:3357.
52. Dombernowsky P., Smith I., Falkson G., et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998, 16:453.
53. Nabholtz J.M., Buzdar A., Pollak M., et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000, 18:3758.
54. Hoctin-Boes G., Yates R., Steinberg M. Letrozole for advanced breast cancer. J Clin Oncol 1998, 16:2892.
55. Mouridsen H., Gershanovich M., Sun Y., et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001, 19:2596.
56. Paridaens R.J., Dirix L.Y., Beex L.V., et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008, 26:4883.
57. Baum M., Budzar A.U., Cuzick J., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359:2131.
58. Buzdar A.U. Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen. Expert Rev Anticancer Ther 2002, 2:623.
59. Forbes J.F., Cuzick J., Buzdar A., et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008, 9:45.
60. Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003, 349:1793.
61. Bliss J, Kilburn L, Coleman R, et al. Disease related outcome with long term follow-up: an updated analysis of the Intergroup Exemestane Study (IES). Presented at the 32nd Annual San Antonio Breast Cancer Symposium. San Antonio (TX), December 10, 2009.